Chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes, CRTH2, is a cognate receptor for prostaglandin (PG) D 2 and, in humans, is suggested to play a functional role in Th2-dependent allergic in¯ammation. While peripheral blood leukocytes expressing high levels of surface CRTH2 have been detected in disease, little is known of the functional signi®cance of CRTH2 in disease etiology. We have utilized a Th2-dependent murine model of FITC-induced contact hypersensitivity to assess the role, if any, CRTH2-PGD 2 may play in the elicitation or maintenance of such pathobiology. Expression of both PGD 2 and CRTH2 in lesional skin was paralleled by the release of the chemoattractants LTB 4 and the chemokine KC, as well as a profuse dermal neutrophilic and eosinophilic in®ltrate, closely paralleling the acute in¯ammatory pathology observed in human atopic dermatitis. A small molecule CRTH2 antagonist, but not a selective PGD 2 R (DP) receptor antagonist, was able to completely abrogate these responses. In¯ammatory cascades mediated by CRTH2 ligation may therefore represent an important early step in the elicitation and maintenance of Th2-dependent skin in¯ammation.
Introduction
Prostaglandin D 2 (PGD 2 ), a product of the arachidonic acid/ cyclooxygenase pathway, is generated at sites of in¯amma-tion and is believed to play an important regulatory role in in¯ammatory and immune responses. Being predominantly released by activated mast cells (1) , PGD 2 has a prominent role in allergic reactions (2±4) due to its ability to induce leukocyte extravasation and by acting as a chemoattractant for Th2 cells, eosinophils and basophils (5±8).
To date, two different G-protein-coupled receptors for PGD 2 are known: the D prostanoid receptor, DP (9) , and the more recently described chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes, CRTH2 (5, 10, 11) . In addition, PGD 2 has been reported to interact with the thromboxane A2 receptor, TP (12) . There is, in addition, the possibility that PGD 2 can be non-enzymatically converted to other bioactive molecules such as 15-deoxy-D12,14-PGJ 2 (15d-PGJ 2 ) and some effects of PGD 2 might be explained indirectly by interaction of 15d-PGJ 2 with nuclear receptors of the peroxisome-proliferator-activated receptor (PPAR) family (13, 14) . However, current evidence suggests that the levels of this metabolite found in vivo are substantially lower than the threshold levels required to activate the PPARs in vitro, raising the question of whether this pathway is relevant (15) .
Through the activation of the DP receptor, PGD 2 signals cAMP elevation and has been implicated in diverse physiological mechanisms such as sleep induction, apoptosis, mucus production, or ocular hypotension (16±19). In contrast, the biological functions of CRTH2 are much less de®ned. In certain human cells, activation of CRTH2 leads to a decrease in cAMP levels (19, 20) and triggers a pertussis-sensitive Ca 2+ signal (5, 7) , suggesting that CRTH2 couples to a G protein of the Ga i/o class.
Although the tissue expression pro®les seem to differ between mouse (11) and man (19) , the high expression levels of CRTH2 in Th2 lymphocytes, basophils and eosinophils in both species imply a major role of CRTH2 in allergic diseases (7, 8, 10, 21, 22) . Indeed, it has been shown that CRTH2 levels on circulating T cells correlate with the severity of atopic dermatitis (23, 24) , and recently it was demonstrated that CRTH2, but not DP or TP, is responsible for PGD 2 -induced chemotaxis of Th2 lymphocytes, eosinophils, basophils and monocytes (6±8,25).
13,14-dihydro-15-keto-PGD 2 (DK-PGD 2 ) (25) is a selective CRTH2 agonist without activating DP up to 30 mM (7), and has been useful in characterizing CRTH2 effects in cellular systems compounded by the presence of DP, although DK-PGD 2 does weakly bind DP (26) . Recent studies have illustrated that the biological activity of CRTH2 may differ between human and rodent leukocytes (26) ; however in vitro evidence for direct signal transduction through CRTH2 in mouse or rat leukocyte subpopulations has thus far been dif®cult to prove in our hands. We were therefore interested in a more detailed determination of the biological effects mediated by CRTH2 as a correlate to determinations of in vivo ef®cacy of small molecule, speci®c CRTH2 inhibitors in murine model systems. As an initial investigation we directly injected DK-PGD 2 into mouse skin. The ensuing in¯ammation observed has been further characterized using an FITC-painted skin model for contact hypersensitivity, and the effects of the small molecule antagonist Ramatroban/BAY u3405 determined (8) . Our studies indicate that CRTH2 activation may play a signi®cant role in Th2-dependent in¯ammatory skin disorders, and that this effect is certainly inhibitable by speci®c antagonists. 4 , KC and MIP-2 were measured by speci®c DuoSet ELISA Development kits (R&D systems).
Methods

Chemicals and reagents
All chemicals not further speci®ed were obtained from Wako Chemicals (Osaka, Japan).
Mice
Female Balb/c mice were obtained from JCR (Charles River, Kanagawa, Japan), maintained under speci®c pathogen-free conditions, and used at 7±8 weeks of age. WBB6F1-W/W v mice and WBB6F1-+/+ mice were purchased from SLC (Shizuoka, Japan). Animals were kept under standard conditions in a 12 h day/night rhythm with free access to food and water ad libitum. All animals received humane care and the studies have been approved by the internal ethic committee in accordance with the guidelines recommended by JALAS (Japanese Association of Laboratory Animal Science).
Induction of contact hypersensitivity (CHS)
For FITC sensitization, 400 ml of 0.5% FITC dissolved in acetone:dibutylpthalate (1:1, DBP) were painted onto the shaved abdominal skin on days 0 and 1. Six days later (day 6), mice were challenged by applying 20 ml of 0.5% FITC onto both sides of the right ear.
The ear thickness of all mice was measured by an engineer's micrometer (Mitutoyo, Japan). Animals were challenged on the right ear with FITC in DBP. DBP alone was applied to the left ear as a solvent control. Challenge-induced increases in ear thickness were measured at various time points thereafter. The CHS response was calculated as a function of challenge-induced increases in ear thickness according to the following formula: Increase in ear thickness = [(right ear thickness post challenge ± left ear thickness post challenge) ± (right ear thickness pre challenge ± left ear thickness pre challenge)].
RT±PCR methods for detection of CRTH2
For detection of CRTH2 mRNA, mouse skin was harvested after dorsal injection of PBS or DK-PGD 2 and homogenized. For detection in leukocytes, spleen CD4+, CD8+ T and B lymphocytes were separated by using the mouse CD4, CD8 and B cell negative selection kit and MACS system according to the manufacturer's instructions (Milteny, Bergisch Gladbach, Germany). Monocytes were separated by adhesion after incubation of splenocytes in RPMI 1640 supplemented with 10% FBS for 2 h. For isolation of neutrophils, anti-Gr-1 antibody (PharMingen) positive cells were separated from peripheral blood. The purity of each separated population of leukocytes was >95%. Total RNA was isolated from skin homogenates or leukocytes using RNAzol. The ®rst strand cDNAs were synthesized with random hexamer primers and Superscript Ô II RNase H-reverse transcriptase (Invitrogen, San Diego, CA) and the PCR reactions were carried out with the primers (synthesized by Nihon Gene Laboratories, Sendai, Japan) as follows: mouse CRTH2, 5¢-CATGGCCAACGT-CACACTGAAGC-3¢ and 5¢-TGTTTCTCCAGGGACCGCTCA-GAC-3¢; mouse b2 microglobulin as a standard, 5¢-GAG-AATGGGAAGCCGAACA-3¢ and 5¢-TATCAGTCTCAGTGGG-GGTG-3¢. For each PCR reaction, the samples were ®rst denatured at 95°C and ampli®ed by 35 cycles of PCR (95°C, 1 min: 65°C, 0.5 min: 72°C, 1 min).
Immunopharmacological studies
For Ab treatment, mice received an intravenous injection of 100 mg per mouse of anti-KC antibody plus Control Ig (rat IgG2b), anti-MIP antibody plus Control Ig (rat IgG2a), anti-KC antibody plus anti-MIP antibody or the corresponding control Igs (rat IgG2a+ rat IgG2b) in a total volume of 0.2 ml, 30 min prior to challenge.
Histological examinations
Ears and back skins were ®xed for 30 h in zinc ®xative (0.05% calcium acetate, 0.5% zinc acetate, 0.5% zinc chloride in 0.1 M Tris±HCl buffer pH7.4) at room temperature, and then embedded in paraf®n. The paraf®n blocks were cut into 2 mm sections for hematoxylin and eosin staining, and cut into 4 mm sections for direct fast scarlet (DFS) stain and immunohistochemistry. To determine the presence of eosinophils, the sections were deparaf®nized, rehydrated and treated with DFS solution (0.2% DFS, 0.8% Na 2 SO 4 in 50% 2-propanol) for 5 min, and then were washed with tap water for 5 min. After overnight incubation in 50% 2-propanol to remove background staining, the samples were counterstained with Mayer's hematoxylin. For immunohistochemistry, the sections were deparaf®nized, rehydrated and treated with 1% BSA for 30 min at room temperature, and then diluted antibodies were applied. After overnight incubation at 4°C, biotinylated antimouse or anti-goat immunoglobulins (DakoCytomation Co. Ltd, Glostrup, Denmark) was applied to the samples for 30 min at room temperature. The samples were treated with 3% H 2 O 2 in methanol for 30 min, and then treated streptavidin± biotin complex±HRP (DakoCytomation) for 30 min. Enzyme activity was developed using 3,3¢-diaminobenzidine (DakoCytomation) and samples were counterstained with Mayer's hematoxylin. Sections were viewed under high power (Q40; BX50 microscope; Olympus, Tokyo, Japan) and photographed using a DP50 digital camera (Olympus).
Evan's blue test
Female mice (Balb/c mice 7 weeks) were injected at two locations intradermally on their shaved backs with increasing concentrations of 0.1±10 mg/site DK-PGD 2 in PBS (±). Three minutes after injection of DK-PGD 2 , the mice were injected i.v. with 0.25 ml of saline containing 1.25 mg of Evan's blue. Four hours after the injection, the mice were sacri®ced and the skin of the back was removed. The severity of edema was assessed by quantifying the extravasated dye (punch diameter: 6 mm) with 0.3 ml of formamide. The extravasated dye density was measured at 620 nm.
Eosinophil peroxidase activity
Skin sections were homogenized in 1 ml ice-cold buffer (0.05 M Tris±HCl pH 8.0 containing 0.1% Triton X-100) using a tissue homogenizer. The samples were then centrifuged at 10 000 g for 20 min at 4°C and the supernatants collected for EPO measurements. The substrate solution (100 ml) consisting of 10 mM O-phenlyenediamine in 0.05 M Tris±HCl and 4 mM H 2 O 2 was added to 20-fold diluted homogenate in buffer (100 ml) in a 96-well microtitre place. The reaction mixture was incubated at room temperature for 60 min before the reaction was stopped by the addition of 100 ml of 2M sulfuric acid. The absorbance at 490 nm was measured in a microplate reader (Labsystems Multiskan Multisoft, Osaka, Japan).
Statistics
Unless otherwise stated, data are expressed as means T SE of at least three independent experiments. Statistical signi®-cance was determined using the unpaired Student's t-test if applicable, or with the Dunnett's or Bonferroni test if variances were non-homogeneous using commercially available statistic software (GraphPad Software, San Diego, CA).
Results
Local reaction to DK-PGD 2 injections into mouse skin
Injection of the CRTH2 agonist, DK-PGD 2 , into the epidermis of mice led to a dose-dependent local in¯ammation characterized by edema formation and signi®cant leukocyte invasion as assessed by the Evan's blue method and histological evaluation, respectively. The maximal response was reached at a DK-PGD 2 dose of 3 mg/injection site within 1±4 h after challenge, and no sign of local in¯ammation was observed at the control injection site where the corresponding volume of solvent was applied instead of DK-PGD 2 ( Fig. 1A±C ). Dermal in®ltrates were observed in the DK-injected mice, the dermal in®ltrates tending to be focused closer to the dermal±epidermal interface, including what appear to be spongiotic lesions dispersed throughout the general area of in®ltration.
To prove the speci®city of the reactions induced by DK-PGD 2 , we pretreated mice with ramatroban, a small molecule CRTH2 antagonist (8), prior to DK-PGD 2 administration. As expected, the pronounced leukocyte in®ltrate in skin sections was completely abrogated (compare Fig. 2A , B and D) as was edema formation (Fig. 2E ). In contrast, pretreatment of mice with dexamethasone had no effect (Fig. 2C ).
In line with these observations, mRNA for CRTH2 was detectable in skin specimens obtained from DK-PGD 2 -challenged but not from vehicle-treated control sites (Fig. 3A) . CRTH2 mRNA expression was not detectable in DK-PGD 2 -challenged skin of mice pretreated with ramatroban (R) or dexamethasone (D) (Fig. 3A) . In addition, numerous immune cells isolated and puri®ed from naive mice expressed high mRNA levels for CRTH2 (Fig. 3B) .
In an attempt to identify the cell population being recruited into the dermal and epidermal layers by DK-PGD 2 , we stained the skin sections with a set of antibodies speci®c for various mouse leukocyte populations: surprisingly, the presence of B cells (B220 + ), T cells (CD3 + , CD4 + , CD8 + ), Langerhans cells (LC), monocytes and macrophages (stained with F4/80), did not signi®cantly differ between sections taken from DK-PGD 2 -treated and control animals, i.e. only a few cells stained positive (Fig. 4A , B and data not shown). In addition, HE staining did not reveal any evidence for signi®cantly high numbers of eosinophils being recruited following DK-PGD 2 injection into the epidermis (data not shown). However, almost all cells in the skin sections from DK-PGD 2 challenged mice stained positive when exposed to the neutrophil-speci®c Ab Ly-6G ( Fig. 4C and D) which is in line with the highest mRNA signal for CRTH2 among all murine cell types investigated (c.f. Fig. 3B and data not shown). In addition, a signi®cantly increased number of activated macrophages as assessed by the antibody directed against the activation marker Mac-3 was observed in samples from DK-PGD 2 -treated animals (Fig. 4E±H) .
Thus, intradermal activation of CRTH2 primarily leads to a local in¯ammatory reaction characterized by in®ltrating neutrophils, activated macrophages and edema formation.
DK-PGD 2 does not directly stimulate mouse neutrophil migration or signal transduction in vitro
As a correlate to the in vivo neutrophil in®ltration of injection sites, we assessed the effect of DK-PGD 2 on neutrophil migration and signaling in vitro. Contrary to expectations, no induced migration or activation was observed in response to DK-PGD 2 over a wide concentration range. Surprisingly, the basal migration and chemoattractant-induced (LTB 4 , KC) migration of isolated peripheral blood neutrophils from mice was slightly, yet consistently, inhibited in the presence of DK-PGD 2 (data not shown). Since these leukocytes express DP1 as well as CRTH2, and it was known that DK-PGD 2 has an effect, albeit at lower potency, on DP1, we postulated that there may have been preferential activation of DP1 and inhibition of migration via the cAMP signaling pathway. Contrary to expectation however, there was no effect of the DP antagonist BWA868C in the presence of DK-PGD 2 and no induction of cAMP as measured by ELISA, in the DK-PGD 2 -stimulated neutrophils (not shown). In addition to these studies, investigations of calcium mobilization (in whole populations or at the single cell level) and ERK phosphorylation all failed to reveal any activity, suggesting a total lack of direct signaling by DK-PGD 2 compared with standard controls (not shown).
The role of CRTH2 in CHS in the mouse
In light of the prominent recruitment of neutrophils into the skin in response to DK-PGD 2 which may be counter-intuitive to a role of CRTH2 in a chronic Th2-mediated allergic in¯ammatory state (5,7), we were interested in determining the presence and role of CRTH2 in a more pathologically relevant animal model of skin in¯ammation. The FITC-painted skin CHS model was chosen, as this displays considerable Th2-dependency (27, 28) . Following a regimen of sensitization and ensuing challenge of the ear by FITC (see Methods for details), a CHS reaction as assessed and quanti®ed by the measurement of ear thickness upon local FITC challenge was reproducibly obtained in Balb/c mice. Preliminary examinations revealed high enzymatic activity of eosinophil peroxidase in the lesions, but not in skin samples taken from the control ears, indicating the in®ltration, and potentially activation, of eosinophils in response to FITC. High power photomicrographs of the lesional skin revealed a signi®cant presence of eosinophils in the dermal layer in addition to leukocyte-®lled microabscesses (Fig. 5A) . The edematous reaction peaked at 24 h after challenge and lasted for more than 3 days (data not shown).
We ®rst determined whether CRTH2 and its endogenous ligand, PGD 2 , would be detectable in skin lesions. Indeed, signi®cant CRTH2 mRNA signals were seen in ear samples 24 h after the FITC challenge but not in control ears. CRTH2 was not detectable at earlier time points, indicating that FITC was most likely inducing recruitment of CRTH2-expressing cells following antigen presentation in the draining afferent lymph nodes. In line with this interpretation, the kinetics of PGD 2 release upon FITC challenge preceded Quantitation of dye leakage around the injection site was assessed on skin diameters of 6 mm and assessment of Evan's blue concentrations at 620 nm (see Methods). (C) Histological evaluation by H&E staining of the injection site was performed as detailed in Methods. A total of three mice per treatment were used and the experiment was performed a minimum of n = 3 times. *P = 0.05; **P = 0.01 by Dunnett's test. the induction of CRTH2 message as shown in Fig. 5(B) and (C), respectively. Together, these ®ndings present evidence for PGD 2 /CRTH2 in elicited CHS and are suggestive of a potential causal role in the establishment of in¯ammatory in®ltrates.
Ramatroban, a CRTH2 antagonist, protects mice from Th2-dependent CHS We then tested ramatroban for its inhibitory potential in this CHS model. A dose-dependent, highly signi®cant reduction of the FITC-induced ear thickness was observed in mice pretreated with ramatroban, and the EPO activity was completely reduced to control levels. Importantly, the TP antagonist ridogrel was without any effect on all parameters, suggesting that ramatroban's ef®cacy was most likely due to its CRTH2 receptor blockade (Fig. 6A and B) . Further studies utilizing orally-administered CRTH2-selective small molecule antagonists have also shown similar ef®cacy in reducing the in¯ammation (data not shown).
Histological examinations of the challenged mouse ears con®rmed those ®ndings: profuse leukocyte in®ltrates were seen 24 h after FITC challenge compared to PBS-treated controls, with both dermal and epidermal in®ltration. Foci of in¯ammatory aggregates and microabscesses were observed in the epidermis, reminiscent of subcorneal pustules and neutrophilic spongiosis typically observed in acute and subacute dermatitis. Indeed, the microabscesses contained signi®cant proportions of intact and degranulated eosinophils, as well as lymphocytes, neutrophils and monocyte/macrophages (Fig. 7A) . Overall, the model correlates well with the acute manifestations of the IgE-dependent cutaneous latephase allergic reaction often found in atopic dermatitis patients (29) . Again, ramatroban, but not ridogrel (TP antagonist) or BWA868C (DP antagonist), abrogated the FITCinduced cell in¯ux as shown in Fig. 7(B±D) . Importantly, the subcorneal abscesses were completely absent following ramatroban treatment, indicating a crucial role for CRTH2 in the formation of these pathological structures.
SurprisinglyÐbut in accordance with what we have found upon DK-PGD 2 injection (c.f. Fig. 4 )Ðleukocyte typing revealed that the majority of cells were neutrophils, although there were eosinophils, macrophages and lymphocytes visibly present. Whether the neutrophils were activated is dif®cult to say since measurements of neutrophil elastase or myeloperoxidase have not been undertaken. Ramatroban clearly inhibited neutrophilia, while the DP antagonist had a moderate effect and ridogrel completely lacked ef®cacy (Fig. 8A±E) . Though obvious, the number of cells staining positively for the eosinophil dye DFS was small compared to the neutrophil numbers ( Fig. 8F and G) , however, considerably greater than are found in normal (unchallenged) skin, and, more surpris- ingly, this in®ltrate was not signi®cantly affected by any receptor antagonist (data not shown).
The presence of neutrophil chemoattractants LTB 4 , KC and MIP-2 may contribute to the neutrophil in¯ammation
The leukocyte in®ltration provoked during the CHS reaction induced by FITC in Balb/c mice is most likely in part mediated by the products of activated mast cells (K. Takeshita, T. Yamasaki, S. Akira, F. Gantner and K. B. Bacon, submitted for publication). Measurements of three well-characterized murine chemoattractants likely synthesized or induced following mast cell activation, LTB 4 and the chemokines KC and MIP-2 (30), revealed a time-dependent increase in these mediators over the duration of the CHS reaction. LTB 4 kinetics of release showed an early peak (1 h) followed by a more sustained release over 8 h prior to returning to baseline (Fig. 9) . The calculated concentration of~0.1 mM would suggest suf®ciently high levels to induce both neutrophil and lymphocyte migration (31, 32) . KC however showed a distinct kinetic with maximal concentrations being achieved at 8±12 h after Fig. 4 . Immunohistological determination of in®ltrating leukocytes. Mice were treated with DK-PGD 2 (3 mg per site), then back skin removed by punch biopsy as detailed in Methods. Staining for speci®c leukocyte markers was performed as described on at least three mice per treatment and ®ve high power ®elds counted. Following staining, sections were photographed under high power (Q40). Arrows indicate speci®cally-stained activated macrophages (Mac-3 antibody).
FITC challenge (Fig. 9) . The calculated maximal concentration (making no assumptions in terms of protein or GAG binding) of 50 pM while low, would still promote signi®cant neutrophil migration, if assessed in in vitro assays (33) . In contrast, however, MIP-2 showed a biphasic kinetic peaking at 30 min and then at 4±8 h post-challenge (Fig. 9) . Similarly, the apparent maximal concentration of 300 pM would be well within the range of effective concentrations, and close to the optimal concentration of MIP-2 for promoting migration of neutrophils.
Using the FITC model to assess this possibility, antibodies speci®c to murine KC and MIP-2 were injected (i.v.) into mice 30 min prior to FITC challenge and the ears assessed for edema from T = 0 to T = 24, and histologically after 24 h (to parallel the kinetic). As shown in Fig. 10(A) , there was a signi®cant decrease in edema as early as the 4 h period when either antibody was used independently and >50% inhibition in swelling when the antibodies were combined. In contrast, no inhibition was observed in mice treated with anti-MCP-1 antibody (Fig. 10C) . In addition, that this response was secondary to release of mediators from mast cells, was suggested using the WWv mouse (Fig. 10B) . These mice, being de®cient in functional mast cells showed no edematous response to FITC, suggesting the requirement for mast-cell derived mediators in elicitation of the response.
Upon histological analysis of the FITC-challenged ears it was clear that the neutrophil in®ltrates were signi®cantly reduced (Fig. 10D) ; however, this appeared to be restricted to the KC-treated animals. In contrast to the effects of ramatroban, an in¯ammatory in®ltrate still appeared to be present. On closer examination however (H&E stained sections), it was clear that while the migration of the majority of neutrophils had been inhibited, there was a substantial eosinophil presence, in addition to what appeared to be mononuclear cells (possibly activated macrophages). This appeared to be most obvious in the dermis where an almost complete inhibition of neutrophilia was observed, leaving an almost exclusive eosinophilic in®ltrate. 6 . Effect of inhibitors on mouse edema induced by FITC challenge. Mice were subjected to the FITC model as described, and prior to challenge, ramatroban or the TP receptor antagonist, ridogrel, were injected i.v. over a dose range of 1±15 mg/kg. Ear thickness was measured using an engineer's micrometer (Mitsutoyo, Japan). Similarly, measurements of EPO were made using a chemical reaction assay. ***P < 0.01 as assessed using Dunnett's test. The number of mice used per dose was 10. Fig. 5 . Assessment of CRTH2 mRNA in mouse skin following FITC sensitization and challenge. The mouse model of FITC-induced contact sensitivity was performed as described in Methods. Following challenge with FITC, mouse ears were removed for immunohistochemistry (A) and RT±PCR analysis of CRTH2 (B).`C' represents the control and`1±3' represent the individual mice. In conjunction, PGD 2 as measured by ELISA over the same time course (C). n = 3 mice per time point were used. *P = 0.05 as measured using Student's t-test.
Discussion
Results generated from the present experiments further detail the propensity for DK-PGD 2 , a selective CRTH2 agonist, to promote murine leukocyte in®ltration in an in¯ammatory setting (26) . The profuse in®ltrates, reminiscent of the acute phase Th2-mediated allergic response in part corroborates biological effects predicted from the in vitro human cell activity (5±7). What is dif®cult to reconcile is the lack of obvious in vitro effects in numerous validated bioassays for murine leukocytes. Indeed, in our hands to date, only the activation (phosphorylation) of p42/p44 ERK has been unequivocally proven, in murine splenocytes and CD4+ T cells derived from mouse spleen (H. Sugimoto, M. Shichijo and K. B. Bacon, unpublished data). Analyses of cell activation in vivo suggest a direct effect on rat leukocytes (26), however, there has to date been little if any evidence in the literature for de®ned functional responses to DK-PGD 2 /CRTH2 activation.
In an analysis of neutrophil activation in vitro, the only suggestion of direct DK-PGD 2 -mediated activity was the noticeable, yet insigni®cant, inhibition of basal and chemoattractant-induced migration. While counter-intuitive, such a ®nding may have signi®cant relevance to the pathology observed in the DK-induced and CHS models. We have seen that the release of PGD 2 occurs over the entire period of 24 h, peaking at around 4 h. In the DK-PGD 2 skin injection model, peak in®ltrates were seen at 4 h, while in the FITC CHS model, signi®cant in®ltration was observed at 1 h postchallenge, with peak in®ltrates being observed at 8 h. In the DK-PGD 2 skin injection model, it is arguable that pre-formed/ stored chemoattractants are released from activated cells in the dermal/epidermal layers that induce the neutrophil in¯ux and DK-PGD 2 retains the cells by virtue of its inhibitory activity on migration. Similarly, in the more complex setting of FITCinduced CHS, preformed or locally generated chemo- attractants over the course of the sensitization and challenge period prime or induce the migration of cells, and as the concentration of PGD 2 rises, the cells are retained at the challenge site. It is clear from these hypotheses that only a more comprehensive analysis of the kinetics of chemoattractant generation will satisfactorily clarify what role CRTH2 activation on leukocytes serves. However, our preliminary investigations into these phenomena suggest that chemoattractants (LTB 4 , MIP-2 and KC) are synthesized and released in suf®cient concentrations and with a kinetic paralleling that of PGD 2 and the leukocyte in®ltrates, thus may ful®l this role at least for neutrophils. One surprising ®nding, however, was the apparent lack of ef®cacy of the anti-MIP-2 antibody in reducing the neutrophilia, although it appeared ef®cacious in reducing the edema. It will be interesting to further de®ne the mechanistic speci®city of this apparent discrepancy between two ligands that supposedly interact at the same receptor, CXCR2.
In the current experiments, it was intriguing to ®nd that DK-PGD 2 failed to promote neutrophil migration in vitro on the one hand, while ramatroban was capable of completely eliminating all in®ltrates following DK-PGD 2 injection. Further, DK-PGD 2 was not capable of priming cells to respond to other chemoattractants; rather it desensitized the reaction. An explanation for such a discrepancy may center on the kinetics of antagonism by ramatroban. In the direct injection scenario, DK-PGD 2 may have been acting on an as yet uncharacterized expressor of CRTH2 in the mouse (mast cells, endothelium, ®broblast, Langerhans cells), inducing the release of secondary chemoattractants. Alternatively, DK-PGD 2 may simply induce chemokinetic priming of cells and not the directed, haptotactic migration. In addition, or alternatively, DK-PGD 2 may increase certain adhesion receptors that can promote the migrationÐa phenomenon unlikely to become evident in the arti®cial environment of the transwell chemotaxis assay. However, using murine cells, we have not observed any change in surface expression of more than 20 surface receptors associated with adhesion and cell migration/ activation, including CD11a-c, CD54, CD44, CD28, CD45R, CD23, Gr-1 and CD49d, in response to DK-PGD 2 (H. Sugimoto, M. Shichijo and K. B. Bacon, data not shown). That ramatroban can inhibit the response may thus lie in selective down-regulation of these entities, and/or inhibition of chemokinetic priming of leukocytes in the circulation; hence their migration out of the circulation.
Given the profound effects of CRTH2 antagonists on the overall pathology of the FITC CHS model, it will be important to further dissect the potential to inhibit the individual components responsible for the gross pathology. Understanding such regulation may further contribute to our understanding of how PGD 2 and CRTH2 are effecting such pathology. For example, it is well-established that the hapten contact sensitizers promote differential T lymphocyte responses (27, 28, 34) . A fundamental characteristic of this acquired immune response is the T lymphocyte and its ability to provide the necessary signals for antibody generation in addition to secreting IL-5 and promoting eosinophil in®ltration. In our analyses, there was no signi®cant effect on the dermal eosinophil in®ltrate as assessed by histological examination of the sections. In addition, there is no noticeable effect on T-cell Fig. 10 . Effect of antibodies to murine KC and MIP-2 on the FITC-induced neutrophil in®ltrates. Polyclonal anti-mouse KC and MIP-2 antibodies (see Methods) were administered i.v. at 100 mg/mouse. Thirty minutes later, the mice were challenged with FITC as described. After 24 h (the optimal time for neutrophil in®ltrates), the mice were sacri®ced and the ear thickness measured using a mircometer screwguage (A), after which the ears were sectioned for histological analysis using H&E and anti-Ly-6G antibody (D). At least 10 mice per challenge and time point were used. Mast cell de®cient mice (B) and antibody to MCP-1 (C) were used as negative controls in the experiment. numbers (although a thorough statistical analysis has not been performed). Two important caveats must be detailed here; (i) there was an almost complete reduction in the EPO measured from the injection sites; and (ii) we did not perform differential staining using speci®c Th1 vs Th2 markers for the T lymphocyte populations. If the disease model is a suitable correlate for human AD, measurements of EPO could re¯ect the degree of degranulation or eosinophil cytolysis, especially if morphologically intact eosinophils are still identi®able (35) . Since we have not observed marked changes in dermal eosinophils in histology sections, it is unlikely that the EPO measurements represent degranulated cells. However, the complete absence of the microabscesses following ramatroban treatment is the likely reason for dramatically reduced EPO.
Secondly, given that no Th1/Th2 differential staining was performed, it is dif®cult for us to conclude that one population of CRTH2-expressing T cells has been affected over another. One cell type that has not been analyzed in these studies is the Langerhans cell (LC). Given that this is the ®rst line of defence in hapten recognition and presentation to the T cells in the afferent lymph nodes (27) , it is critical to investigate the effects of DK-PGD 2 and ramatroban on these cells. It has been published that LC express both DP and CRTH2 (25, 36) . However, the major biological responses to PGD 2 seen in in vitro and in vivo models analyzing LC and DC maturation, migration and antigen presentation suggest that the major receptor activated is DP, and that the majority of responses are inhibitory/antiin¯ammatory, in direct contrast to what one observes with DK-PGD 2 injections and the CHS model. In our hands, murine monocyte-derived DC also did not show robust signaling (calcium mobilization and ERK phosphorylation) in response to DK-PGD 2 , and failed to augment Th2-derived IL-4 release in a co-culture assay in vitro (K. Nakashima, F. Gantner, M. Shichijo and K. B. Bacon, unpublished data). It will therefore be critical to determine the contributions of DP and CRTH2 under a variety of stimulatory conditions in naive T lymphocytes, the speci®c skin-homing T cells and dermal DC and LC.
The ®nding that ramatroban (and other selective small molecule CRTH2 antagonists developed in-house, data not shown) can completely abrogate the experimentally induced contact dermatitis (as measured by ear swelling) is a particularly encouraging signal for the development of effective therapeutics for dermatoses characterized by such clinical manifestations. Of particular interest was the ®nding that the signi®cant levels of EPO were measurably reduced. It is thus likely that the high EPO activity (c.f. Fig. 6B ) is an indicator of the numbers of necrotic eosinophils present in the spongiotic lesions/abscesses, thus effective reduction in this parameter suggests that targeting CRTH2 will be an extremely effective measure in reducing the symptoms and perhaps even the etiology of AD. Of critical importance is the assessment of such an approach in a more chronic setting. The murine model currently employed has been investigated in both an acute (1 week) and more chronic (3 week) protocol. In humans, the more chronic manifestation of AD is characterized by epidermal hyperplasia upon which can be superimposed exacerbations of acute dermatitis, the pathology being typi®ed by the eosinophilic and neutrophilic in®ltrates and spongiotic lesions. Effects of ramatroban and other selective antagonists for CRTH2 are therefore being evaluated in the more chronic setting and have thus far been found to be effective (our unpublished results). Given that ramatroban is well characterized to be a potent inhibitor of the thromboxane A2 receptor, it was important to show that the inhibitory effects observed in our system were not mediated by such effects. In addition, there is a strong association of the 795 TT TXA2R polymorphism in AD, seen in a Japanese cohort (37) . Using the speci®c TXA2R inhibitor, ridogrel, there was apparently little if any contribution of this receptor±ligand pair to the acute in¯ammation observed. We cannot however rule out the possibility that there were some minor yet pathologically signi®cant effects of ramatroban on vascular leakage that in turn would impact the emigration of cells to the periphery.
Since elevated PGD 2 levels are found in allergen-challenged skin from AD patients, as well as in samples from atopic donors (38, 39) , and an increased number of peripheral blood CRTH2+ T lymphocytes are detected in the CLA+ skinhoming lymphocyte population from AD patients (40) , it is likely that the PGD 2 /CRTH2 system is playing a role in the in¯ammatory dermal in®ltrate in this disease. Even though numerous chemoattractants capable of attracting the speci®c leukocyte populations are elevated in AD skin (41, 42) , the ability of a single ligand±receptor system to control the recruitment of all the relevant populations is thus far unknown. Eotaxin, an eosinophil and Th2 cell chemoattractant, has not been shown to promote human neutrophil or monocyte migration. In our hands, human T lymphocytes with either a Th1 or Th2 cytokine pro®le have been shown to express CCR3 and migrate in vitro in response to eotaxin (H. Sugimoto and K. B. Bacon, unpublished data). Similarly, IL-8, a well-known neutrophil chemoattractant, has much weaker pro-migratory effects on lymphocytes (43) . Leukotriene B 4 , for many years known to be a neutrophil and T lymphocyte chemoattractant was recently shown to promote effector CD4 and CD8, Th1 and Th2 lymphocyte migration in a model of allergic in¯am-mation (44) . While this may contribute signi®cantly to the proin¯ammatory cascade in AD (41), the weak effects of LTB 4 on eosinophils argues against a prominent role in the disease etiology.
We have identi®ed a potential role for CRTH2 and PGD2 in the elicitation of in¯ammation in a dermatological context. An initiating or maintenance role for CRTH2 is dif®cult to prove categorically and ®nal proof of the fundamental role of this system will come only from the use of speci®c antagonists to CRTH2 in a clinical setting.
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